Scarica l'app Stockscreener
26.97
2.12%
0.56
Dopo l'orario di chiusura:
26.97
Precedente Chiudi:
$26.41
Aprire:
$25.49
Volume 24 ore:
1.65M
Relative Volume:
1.33
Capitalizzazione di mercato:
$2.22B
Reddito:
-
Utile/perdita netta:
$-154.65M
Rapporto P/E:
-11.34
EPS:
-2.3786
Flusso di cassa netto:
$-142.43M
1 W Prestazione:
+14.23%
1M Prestazione:
-8.02%
6M Prestazione:
-33.34%
1 anno Prestazione:
+92.64%
Intervallo 1D:
$25.49
$27.03
Intervallo di 1 settimana:
$23.30
$29.09
Portata 52W:
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
26.97 | 2.22B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Earnings Miss: Whats the RSI of Mineralys Therapeutics Inc stock2026 Levels & Capital Protection Trading Alerts - baoquankhu1.vn
Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock By Investing.com - Investing.com Australia
Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares - MarketBeat
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 3,000 Shares of Stock - MarketBeat
Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock By Investing.com - Investing.com Australia
Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock - Investing.com
Mineralys Therapeutics CEO Congleton sells $1.97 million in MLYS stock - Investing.com
Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan
Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan
IPO Launch: How sensitive is Mineralys Therapeutics Inc to inflationMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Mineralys Therapeutics (NASDAQ:MLYS) Director Acquires $7,354,269.00 in Stock - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Mineralys Therapeutics Surges on FDA Milestone Buzz - TipRanks
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Insider Monkey
Mineralys Therapeutics(MLYS.US) Director Buys US$8.76 Million in Common Stock - 富途牛牛
Mineralys Therapeutics (NASDAQ: MLYS) insider sells 3,000 shares - Stock Titan
Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan
RA Capital funds add 369,000 Mineralys (NASDAQ: MLYS) shares - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 12.4%What's Next? - MarketBeat
Investors Purchase High Volume of Mineralys Therapeutics Put Options (NASDAQ:MLYS) - MarketBeat
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Ex-Copaxone launch executive joins Immunic board as MS trial nears - stocktitan.net
(MLYS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
SG Americas Securities LLC Buys 130,758 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Major Insider Power Move Signals Growing Confidence in Mineralys Therapeutics - TipRanks
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys reports 2025 results, advances hypertension drug review - MSN
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer By Investing.com - Investing.com Australia
Biopharma Co. Gives New CLO $3.6 Million In Stock Awards - Law360
Mineralys Therapeutics grants inducement equity awards to two new employees - msn.com
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer - TipRanks
Mineralys Grants Inducement Equity Awards to New Employee - MyChesCo
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - citybiz
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer - Investing.com
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer - MarketScreener
Mineralys Therapeutics Appoints Jeffrey A. Munsie As Chief Legal Officer - TradingView
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA AcceptanceWhat's Changed - simplywall.st
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Earnings Beat: Whats the profit margin of Mineralys Therapeutics IncQuarterly Risk Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Growth Value: What is the implied volatility of Mineralys Therapeutics Inc2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):